"Turning the tables"--making normal marrow resistant to chemotherapy.

J. Bertino

DOI: https://doi.org/10.1093/JNCI/82.15.1234

1990-08-01

Journal of the National Cancer Institute

Abstract:In the past several years, gene therapy has received a great deal of attention not only because of its potential for treatment of human disease, but also because of the ethical and moral issues that its use raises {1-4). Although the possibility of using gene transfer to correct genetic deficiencies has been the major thrust of investigations, also attractive is the use of gene transfer to impart properties to certain cells (e.g., marrow stem cells and T cells) that would allow improved treatment of neoplastic disease. Successful treatment of a genetic disorder requires that the gene transferred be incorporated into the DNA of a stem cell so as to remain with the individual for life. In contrast, gene therapy of malignant disease will likely only require transient expression of the desired protein, perhaps by committed progenitor cells. Thus, this goal may be more readily achieved. The resistance of tumor cells to drugs, recognized to be a major obstacle in the treatment of cancer, is not accompanied by increased resistance of normal host cells. The prospect of increasing tolerance of normal bone marrow cells to a drug by gene transfer, and thus being able to increase the intensity of treatment, is an attractive one, particularly for the treatment of those malignancies that demonstrate a reasonable dose response to drugs. Several genes that code for proteins that are targets for cancer drugs have been cloned, and mutations in these genes have been described that result in resistance to the target drug (table 1). These genes are all candidates for use for bone marrow progenitor cell gene transfer. There already has been a significant amount of work with dihydrofolate reductase, the target enzyme for methotrexate, indicating that marrow tolerance to this drug is improved after this gene is introduced into marrow progenitor cells (5). Our laboratory has been attempting to develop additional dihydrofolate reductase complementary DNA clones with mutations that express altered enzymes with good catalytic activity suitable for this purpose (6).